| |
| |
|
| Insider
Information: |
Pfreundschuh Peter P. |
| Relationship: |
Chief Financial Officer |
| City: |
Morris Plains |
| State: |
NJ |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
224,707 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$4,306,405 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
224,707 |
|
|
| Total
Value |
$4,306,405 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
9
|
|
Stock
price went up :
|
0
|
3
|
| Stock
price went down : |
0
|
6
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -100.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Immunomedics Inc |
IMMU |
Chief Financial Officer |
2015-08-20 |
29,706 |
2014-08-14 |
0 |
Premium* |
|
|
Sucampo Pharmaceuticals, Inc. |
SCMP |
CFO |
2018-02-13 |
0 |
2017-09-30 |
0 |
Premium* |
|
|
Urogen Pharma Ltd. |
URGN |
Chief Financial Officer |
2020-10-15 |
10,405 |
2019-08-20 |
0 |
Premium* |
|
|
Korro Bio |
KRRO |
Chief Financial Officer |
2022-02-22 |
8,927 |
2022-02-14 |
0 |
Premium* |
|
|
Voyager Therapeutics, Inc. |
VYGR |
Chief Financial Officer |
2024-02-21 |
175,669 |
2022-10-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| VYGR |
Voyager Therapeutics, Inc... |
Chief Financial Officer |
• – – |
2024-02-21 |
4 |
S |
$7.46 |
$28,079 |
D/D |
(3,764) |
175,669 |
0 |
% |
|
| VYGR |
Voyager Therapeutics, Inc... |
Chief Financial Officer |
• – – |
2024-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
179,433 |
0 |
- |
|
| VYGR |
Voyager Therapeutics, Inc... |
Chief Financial Officer |
• – – |
2023-10-03 |
4 |
S |
$6.99 |
$94,833 |
D/D |
(13,567) |
149,433 |
0 |
% |
|
| VYGR |
Voyager Therapeutics, Inc... |
Chief Financial Officer |
• – – |
2023-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
38,000 |
163,000 |
0 |
- |
|
| VYGR |
Voyager Therapeutics, Inc... |
Chief Financial Officer |
• – – |
2022-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
125,000 |
125,000 |
0 |
- |
|
| KRRO |
Korro Bio |
Chief Financial Officer |
• • – |
2022-02-22 |
4 |
S |
$3.53 |
$5,442 |
D/D |
(1,542) |
8,927 |
0 |
- |
|
| KRRO |
Korro Bio |
Chief Financial Officer |
• • – |
2022-02-18 |
4 |
S |
$3.88 |
$5,443 |
D/D |
(1,404) |
10,469 |
0 |
- |
|
| KRRO |
Korro Bio |
Chief Financial Officer |
• • – |
2022-02-17 |
4 |
S |
$4.20 |
$5,443 |
D/D |
(1,296) |
11,873 |
0 |
- |
|
| KRRO |
Korro Bio |
Chief Financial Officer |
• • – |
2022-02-16 |
4 |
S |
$4.43 |
$5,443 |
D/D |
(1,229) |
13,169 |
0 |
- |
|
| KRRO |
Korro Bio |
Chief Financial Officer |
• • – |
2022-02-15 |
4 |
S |
$4.33 |
$5,834 |
D/D |
(1,347) |
14,398 |
0 |
- |
|
| KRRO |
Korro Bio |
Chief Financial Officer |
• • – |
2022-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
15,745 |
0 |
- |
|
| URGN |
Urogen Pharma Ltd. |
Chief Financial Officer |
• – – |
2020-10-15 |
4 |
S |
$21.72 |
$52,248 |
D/D |
(2,400) |
10,405 |
0 |
% |
|
| URGN |
Urogen Pharma Ltd. |
Chief Financial Officer |
• – – |
2020-10-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,917 |
12,805 |
0 |
- |
|
| URGN |
Urogen Pharma Ltd. |
Chief Financial Officer |
• – – |
2020-09-01 |
4 |
S |
$22.82 |
$11,615 |
D/D |
(509) |
7,888 |
0 |
% |
|
| URGN |
Urogen Pharma Ltd. |
Chief Financial Officer |
• – – |
2020-09-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,042 |
8,397 |
0 |
- |
|
| URGN |
Urogen Pharma Ltd. |
Chief Financial Officer |
• – – |
2020-07-27 |
4 |
S |
$23.51 |
$3,315 |
D/D |
(141) |
7,355 |
0 |
% |
|
| URGN |
Urogen Pharma Ltd. |
Chief Financial Officer |
• – – |
2020-07-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
417 |
7,496 |
0 |
- |
|
| URGN |
Urogen Pharma Ltd. |
Chief Financial Officer |
• – – |
2020-05-20 |
4 |
S |
$25.07 |
$8,975 |
D/D |
(358) |
7,079 |
0 |
% |
|
| URGN |
Urogen Pharma Ltd. |
Chief Financial Officer |
• – – |
2020-05-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,041 |
7,437 |
0 |
- |
|
| URGN |
Urogen Pharma Ltd. |
Chief Financial Officer |
• – – |
2020-04-27 |
4 |
S |
$24.35 |
$3,433 |
D/D |
(141) |
6,396 |
0 |
% |
|
| URGN |
Urogen Pharma Ltd. |
Chief Financial Officer |
• – – |
2020-04-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
417 |
6,537 |
0 |
- |
|
| URGN |
Urogen Pharma Ltd. |
Chief Financial Officer |
• – – |
2020-02-20 |
4 |
S |
$29.68 |
$10,685 |
D/D |
(360) |
6,120 |
0 |
% |
|
| URGN |
Urogen Pharma Ltd. |
Chief Financial Officer |
• – – |
2020-02-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,042 |
6,480 |
0 |
- |
|
| URGN |
Urogen Pharma Ltd. |
Chief Financial Officer |
• – – |
2020-01-27 |
4 |
S |
$29.28 |
$19,530 |
D/D |
(667) |
4,438 |
0 |
% |
|
| URGN |
Urogen Pharma Ltd. |
Chief Financial Officer |
• – – |
2020-01-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,666 |
5,105 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
